SG Americas Securities LLC Lowers Holdings in Humana Inc. (NYSE:HUM)

SG Americas Securities LLC lowered its position in Humana Inc. (NYSE:HUM) by 60.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,828 shares of the insurance provider’s stock after selling 4,250 shares during the period. SG Americas Securities LLC’s holdings in Humana were worth $717,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of HUM. Atlas Brown Inc. lifted its position in shares of Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares in the last quarter. Moors & Cabot Inc. grew its stake in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock worth $519,000 after purchasing an additional 40 shares in the last quarter. OLD National Bancorp IN lifted its holdings in Humana by 1.8% during the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after buying an additional 45 shares during the period. Your Advocates Ltd. LLP lifted its holdings in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares during the last quarter. Finally, Brooklyn Investment Group lifted its holdings in shares of Humana by 6.7% during the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after purchasing an additional 46 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 2.9 %

Shares of HUM stock opened at $294.18 on Thursday. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $406.46. The stock has a market cap of $35.42 billion, a price-to-earnings ratio of 26.06, a P/E/G ratio of 2.15 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76. The firm has a fifty day moving average of $275.44 and a 200-day moving average of $303.14.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, equities research analysts forecast that Humana Inc. will post 16.11 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank of Canada cut their price target on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Barclays raised their target price on shares of Humana from $253.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 22nd. Bank of America raised shares of Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. KeyCorp assumed coverage on shares of Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Finally, Oppenheimer lowered their target price on shares of Humana from $400.00 to $280.00 and set an “outperform” rating for the company in a research note on Thursday, October 3rd. Nineteen investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $297.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.